Advertisement

Oncology – Treatments and Their Limits

  • Andras SzaszEmail author
  • Nora Szasz
  • Oliver Szasz
Chapter
  • 691 Downloads

Abstract

The fight against cancer is as old as medicine itself. Despite the huge achievements of human kind, and its triumph over many fatal diseases; the war against cancer has not yet been won.

Keywords

Human Medicine Bronchus Cancer Actual Treatment Condition Solid Proof Severe Suffering 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 23.
    Diamandopoulos GT (1996) Cancer: an historical perspective. Anticancer Res 16(4A):1595–1602PubMedGoogle Scholar
  2. 27.
    Contran R, Kumar V, Collins T et al (1989) Robbins Pathologic Basis of Disease. 4th ed. Philadelphia, WB SaundersGoogle Scholar
  3. 28.
    Weinberg RA (1999) One renegade cell. How cancer begins. Basic Books, Parseus Book GroupGoogle Scholar
  4. 29.
    Cairns J (1975) The Cancer Problem. Scientific American 233(5):64–72, 77–78PubMedCrossRefGoogle Scholar
  5. 30.
    Reya T, Morrison SJ, Clarke MF et al (2001) Stem cells, cancer, and cancer stem cells. Nature 414(6859):105–111PubMedCrossRefGoogle Scholar
  6. 31.
    Singh SK, Clarke ID, Terasaki M et al (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63:5821–5828PubMedGoogle Scholar
  7. 32.
    Balkwill F, Charles K, Mantovani A (2005) Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7(3):211–217PubMedCrossRefGoogle Scholar
  8. 33.
    De Visser KE, Eichten A, Coussens LM (2006) Paradoxical roles of the immune system during cancer development. Nature Reviews Cancer 6(1):24–37PubMedCrossRefGoogle Scholar
  9. 34.
    Inagaki J, Rodroguez V, Bodey GP (1974) Causes of death in cancer patients. Cancer Philadelphia 33(2):568–573CrossRefGoogle Scholar
  10. 35.
    Welch HG, Schwartz LM, Woloshin S (2000) Are increasing 5-year survival rates evidence of success against cancer? JAMA 283(22):2975–2978PubMedCrossRefGoogle Scholar
  11. 36.
    Morgan G, Ward R, Barton M (2004) The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies. Clin Oncol (R Coll Radiol) 16(8):549–560Google Scholar
  12. 37.
    Bailair JC, Smith EM (1986) Progress against cancer? The New England Journal of Medicine 314(19):1226–1232CrossRefGoogle Scholar
  13. 38.
    Holleb AI (1986) Progress against cancer? A broader view. CA Cancer Journal for Clinicians 36:243–244CrossRefGoogle Scholar
  14. 39.
    Schoenbach VJ (1999) Descriptive studies and surveillance-solutions. www.epidemiolog.net/evolving/DescriptiveStudiesSolns.pdf Cited 12 September 2007
  15. 40.
    Bailar JC, Gornik HL (1997) Cancer undefeated. The New England Journal of Medicine 336(22):1569–1574PubMedCrossRefGoogle Scholar
  16. 41.
    Pauling L (1989) Quoted by Moss RW: The Cancer Syndrome. Equinox Press, New YorkGoogle Scholar
  17. 42.
    The failed War on Cancer. People Against Cancer. http://www.peopleagainstcancer.com/pdfs/news/20080916n2.pdf. Editorial 12 July 2008
  18. 43.
    Arnold K (2003) Statistics offer insights into progress against cancer. Journal of the National Cancer Institute 95(17):1266–1267PubMedGoogle Scholar
  19. 44.
    Honore BE, Lleras-Muney A (2006) Bounds in completing risks models and the war on cancer. Econometrica 74(6):1675–1698CrossRefGoogle Scholar
  20. 45.
    National Cancer Institute (2003) SEER Cancer Statistics Review. http://seer.cancer.gov/csr/1975_2003/results_merged/topic_year_lost.pdf. 1975–2003
  21. 46.
    National Cancer Institute (2003) Plans and Priorities for Cancer Research. http://plan2003.cancer.gov/inbrief/execsum.htm
  22. 47.
    Surveillance, Epidemiology, and End Results (SEER), National Cancer Institute. www.seer.cancer.gov. 2000
  23. 48.
    Colotta, F., Mantovani, A. (eds.): Targeted therapies in cancer: Myth or reality? American Institute of Physics (AIP) (2007)Google Scholar
  24. 49.
    Frost & Sullivan Market Intelligence (2003) 1996, 2002–2008. Reuters Business Insight, Health CareGoogle Scholar
  25. 50.
    Goldberg R, Pitts P (2006) A working paper of the 21st century FDA task force. Prescription for progress: the critical path to drug development. http://www.manhattan-institute.org/html/fda_task_1.htm. Cited 11 Sept 2007
  26. 51.
    National Center for Health Statistics (2007) Hyattsville. http://www.cdc.gov/nchs/fastats/lcod.htm. Cited 12 Sept 2007
  27. 52.
    BBC News. Thursday, 9 November 2000, 18:08 GMTGoogle Scholar
  28. 53.
    EUROCARE-3 European Cancer Database. www.eurocare.org/profiles/index.html
  29. 54.
    Research America Health Poll, Charlton Research Company. www.researchamerica.org/polldata/2006/longevity_fullresults. Cited 2006
  30. 55.
  31. 56.
    Fear from AIDS rivals worry over cancer (1987) The New York Times. www.query.nytimes.com/gst/fullpage.html?sec=health&res9BODE1DD1E3DF93AA15752C1A961948260. Cited 12 Sept 2007
  32. 57.
    Harima Y, Nagata K, Harima K et al (2001) A randomized clinical trial of radiation therapy versus thermoradiotherapy in stage IIIB cervical carcinoma. Int J Hyperthermia 17(2):97–105PubMedCrossRefGoogle Scholar
  33. 58.
    Feig BW, Berger DH, Fuhrman GM (2006) The M.D. Anderson Surgical Oncology Handbook. Lippincott Williams & WilkinsGoogle Scholar
  34. 59.
    Warburg O (1956) On the origin of cancer cells. Science 123(3191):309–314PubMedCrossRefGoogle Scholar
  35. 60.
    Anderson MW, Reynolds SH, Maronpot RM (1992) Role of proto-oncogene activation in carcinogenesis. Environ Health Perspect 98:13–24PubMedCrossRefGoogle Scholar
  36. 61.
    Meden H, Marx D, Fattahi A et al (1994) Elevated serum levels of a c-erbB-2 oncogene product in ovarian cancer patients and in pregnancy. J Cancer Res Clin Oncol 120(6):378–381PubMedCrossRefGoogle Scholar
  37. 62.
    Attie-Bitach T, Abitbol M, Gérard M (1998) Expression of the RET proto-oncogene in human embryos. Am J Med Genet 80(5):481–486PubMedCrossRefGoogle Scholar
  38. 63.
    Quenby SM, Gazvani MR, Brazeau C et al (1999) Oncogenes and tumor suppressor genes in first trimester human fetal gonadal development. Mol Hum Reprod 5(8):737–741PubMedCrossRefGoogle Scholar
  39. 64.
    Okada Y et al (1996) Expression of fos family and jun family proto-oncogenes during corneal epithelial wound healing. Curr Eye Res 15(8):824–832PubMedCrossRefGoogle Scholar
  40. 65.
    Stiles CD (1985) The biological role of oncogenes-insights from platelet-derived growth factor: Rhoads Memorial Award lecture. Cancer Res 45:5215–5218PubMedGoogle Scholar
  41. 66.
    Fiala ES, Sohn OS, Wang CX et al (2005) Induction of preneoplastic lung lesions in guinea pigs by cigarette smoke inhalation and their exacerbation by high dietary levels of vitamins C and E. Carcinogenesis 26(3):605–612PubMedCrossRefGoogle Scholar
  42. 69.
    Molloy RM, Sonnenberg A (1997) Relation between gastric cancer and previous peptic ulcer disease. Gut 40(2):247–252PubMedGoogle Scholar
  43. 70.
    Friess H, Lu Z, Graber HU et al (1998) Bax, but not bcl-2, influences the prognosis of human pancreatic cancer. Gut 43(3):414–421PubMedCrossRefGoogle Scholar
  44. 71.
    Warburg O (1996) Oxygen, The Creator of Differentiation, Biochemical Energetics. Academic Press, New York In: Warburg O (1996) The Prime Cause and Prevention of Cancer. Revised lecture at the meeting of the Nobel-Laureates on June 30 1966, Lindau, Lake Constance, GermanyGoogle Scholar
  45. 72.
    Schulz TJ, Thierbach R, Voigt A et al (2006) Induction of Oxidative Metabolism by Mitochondrial Frataxin Inhibits Cancer Growth. The Journal of Biological Chemistry 281(2):977–981PubMedCrossRefGoogle Scholar
  46. 73.
    Miles KA, Williams RE (2008) Warburg revisited: imaging tumor blood flow and metabolism. Cancer Imaging 8:81–86PubMedCrossRefGoogle Scholar
  47. 74.
    Heiden MGV, Cantley LC, Thompson CB (2009) Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation. Science 324(5930):1029–1033CrossRefGoogle Scholar
  48. 75.
    Garber K (2004) Energy boost: The Warburg effect returns in a new theory of cancer. Journal Nat Canc Inst 96(24):1805–1806CrossRefGoogle Scholar
  49. 76.
    Seyfried TN, Mukherjee P (2005) Targeting energy metabolism in brain cancer: review and hypothesis. Nutrition & Metabolism 2:30–38CrossRefGoogle Scholar
  50. 77.
    Xiaolong M, Riordan NH (2006) Cancer is a functional repair tissue. Medical Hypotheses 66(3):486–490CrossRefGoogle Scholar
  51. 78.
    Tan BT, Park CY, Ailles Le et al (2006) The cancer stem cell hypothesis: a work in progress. Laboratory Investigation 86(12):1203–1207PubMedCrossRefGoogle Scholar
  52. 80.
    Houghton JM et al (2007) Stem cells and cancer. Seminars in Cancer Biology 17(3):191–203PubMedCrossRefGoogle Scholar
  53. 81.
    Weinberg RA (1998) One Renegade Cell: How Cancer Begins. Basic Books, Member of the Perseus Books Group, New YorkGoogle Scholar
  54. 82.
    Sell S (2004) Stem cell origin of cancer and differentiation therapy. Critical Reviews in Oncology Hematology 51(1):1–28CrossRefGoogle Scholar
  55. 83.
    Krause M, Prager J, Zhou X et al (2007) EGFR-TK inhibition before radiotherapy reduces tumor volume but does not improve local control: differential response of cancer stem cells and nontumorigenic cells? Radiotherapy and Oncology 83(3):316–325PubMedCrossRefGoogle Scholar
  56. 85.
    Tang C, Ang BT, Pervaiz S (2007) Cancer stem cell: target for anti-cancer therapy. The FASEB Journal 21:3777–3785PubMedCrossRefGoogle Scholar
  57. 86.
    Marx J (2007) Molecular Biology: Cancer’s Perpetual Source? Science 317(5841):1029–1031PubMedCrossRefGoogle Scholar
  58. 87.
    Neuzil J, Stantic M, Zobalova R et al (2007) Tumor-initiating cells vs. cancer ‘stem’ cells and CD133: What’s in the name? Biochemical and Biophysical Research Communications 355(4):855–859PubMedCrossRefGoogle Scholar
  59. 88.
    Kartner N, Ling V (1989) Multidrug resistance in Cancer. Scientific Am 260(3):44–51CrossRefGoogle Scholar
  60. 89.
    West BJ (2006) Where medicine went wrong: Rediscovering the Path to Complexity. World Scientific. Publ, New Jersey, LondonCrossRefGoogle Scholar
  61. 90.
    Skrabanek P (1994) The death of human medicine. The Social Affairs Unit, Crowley Esmonde Ltd, SuffolkGoogle Scholar
  62. 91.
    Fox R (1994) Foreword in book: Skrabanek P. The Death of Humane Medicine. Social Affairs Unit, SuffolkGoogle Scholar
  63. 92.
    Horgan J (1997) The end of Science. Broadway books, New YorkGoogle Scholar
  64. 93.
    Milton R (1994) Forbidden Science. Fourth Estate, LondonGoogle Scholar
  65. 94.
    Greider K (2003) The big fix. Public Affairs, New YorkGoogle Scholar
  66. 97.
    Moss RW (1995) Questioning Chemotherapy. Equinox Press, New YorkGoogle Scholar
  67. 98.
    Baron J (1996) Do no harm. In: Messick DM, Tenbrunsel AE (eds) Codes of conduct: Behavioural research into business ethics, Russell Sage Foundation, New York, pp.197–213Google Scholar
  68. 99.
    US Food and Drug Administration (FDA). Critical Path Initiative. http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/default.htm
  69. 100.
    Green S, Benedetti J, Crowley J (2003) Clinical Trials in Oncology. Chapman & Hall/CRC, Boca Raton, LondonGoogle Scholar
  70. 101.
    McGovern DPB, Valori RM, Summerskill WSM et al (2001) Evidence-based medicine. Bios Scientific Publ Ltd, Oxford, UKGoogle Scholar
  71. 102.
    Sackett DL, Rosenberg WM, Gary JA et al (1996) Evidence based medicine: what it is and what it isn’t. BMJ 312(7023):71–72PubMedGoogle Scholar
  72. 103.
    Centre for Evidence-Based Medicine in Oxford (2009) http://www.cebm.net/index.aspx?o=1025
  73. 104.
    Glantz SA (1997) Primer of bio-statistics. McGraw Hill, Health Professions Division, New YorkGoogle Scholar
  74. 105.
    The Office of Cancer Complementary and Alternative Medicine (OCCAM). National Cancer Institute (NCI). http://www.cancer.gov/CAM
  75. 106.
    Eisenberg DM, Kessler RC, Foster C et al (1993) Unconventional Medicine in the United States – Prevalence, Costs, and Patterns of Use. The New England Journal of Medicine 328(4):246–252PubMedCrossRefGoogle Scholar
  76. 107.
    American Public (2005) Complementary and Alternative Medicine in the United States. National Academic Press. http://www.nap.edu/catalog.php?record_id=11182
  77. 108.
    Edwards SJ, Braunholtz DA, Lilford RJ et al (1998) Ethical issues in the design and conduct of randomized controlled trials. Health Technology Assessment, NHS R&D HTA Programme, 15(2):1–146Google Scholar
  78. 110.
    Gifford F (1986) The conflict between randomized clinical trials and the therapeutic obligation. J. Med. Philos 11(4):347–366PubMedGoogle Scholar
  79. 111.
    Benson K, Hartz AJ (2000) A comparison of observational studies and randomized, controlled trials. NEJM 342(25):1878–1886PubMedCrossRefGoogle Scholar
  80. 112.
    Concato J, Shah N, Horwitz RI (2000) Randomized, controlled trial, observational studies, and the hierarchy of research design. NEJM 342(25):1887–1892PubMedCrossRefGoogle Scholar
  81. 113.
    Kennedy D (2004) Clinical trials and public trust. Science 306(5702):1649PubMedCrossRefGoogle Scholar
  82. 114.
    DiTrocchio F (1994) Der grosse schwindel – betrug und falschung in der wissenschaft. Campus Verlag, FrankfurtGoogle Scholar
  83. 115.
    Gardner MJ, Altman DG (1989) Statistics with Confidence, British Medical Journals Book, British Medical Journal, LondonGoogle Scholar
  84. 116.
    Jaynes ET (2003) Probability Theory: The logic of Science. Cambridge University Press, CambridgeCrossRefGoogle Scholar
  85. 117.
    Gauler TC, Weihrauch TR (1997) Placebo-ein wirksames und ungefährliches Medikament? Urban & Schwarzenberg, Munich, Wien, BaltimoreGoogle Scholar
  86. 118.
    Kaptchuk TJ (1998) Intentional ignorance: A history of blind assessment and placebo controls in medicine. Bull Hist Med 72(3):389–433PubMedCrossRefGoogle Scholar
  87. 119.
    Stron FC (1999) The history of the double-blind test. J Pharm Pharmacol 51:237–239CrossRefGoogle Scholar
  88. 120.
    Pappercorn JM, Weeks JC, Cook EF et al (2004) Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. The Lancet 363:263–270CrossRefGoogle Scholar
  89. 121.
    Giacchetti S, Perpoint B, Zidani R et al (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18(1):136–147PubMedGoogle Scholar
  90. 122.
    Possinger K, Kaufmann M, Coleman R (1999) Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer. Anticancer Drugs 10(2):155–162PubMedCrossRefGoogle Scholar
  91. 123.
    Carmichael J, Walling J (1996) Phase II activity of gemcitabine in advanced breast cancer. Semin Oncol 23:77–81PubMedGoogle Scholar
  92. 124.
    Krcyzanowska MK, Pintilie M, Tannock IF (2003) Factors associated with failure to publish large randomized trials presented at an oncology meeting. JAMA 290(4):495–501CrossRefGoogle Scholar
  93. 125.
    Lexchin J, Bero LA, Djulbegovic B et al (2003) Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 326(7400):1167–1170PubMedCrossRefGoogle Scholar
  94. 126.
    Melander H, Ahlqvist-Rastad J, Meijer G et al (2003) Evidence b(i)ased medicine—selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 326:1171–1173PubMedCrossRefGoogle Scholar
  95. 127.
    Stelfox HT, Chua G, O’Rourke K et al (1998) Conflict of interests in the debate over calcium-channel antagonists. NEJM 338(2):101–106PubMedCrossRefGoogle Scholar
  96. 128.
    Choudhry NK, Stelfox HT, Detsky AS (2002) Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA 287(5):612–617PubMedCrossRefGoogle Scholar
  97. 129.
    Baird P, Downie J, Thompson J (2002) Clinical trials and industry. Science 297:2211PubMedCrossRefGoogle Scholar
  98. 130.
    Brecht B (1935) Leben des Galilei. In: Losey J (1975) Galileo, Grove Press, New YorkGoogle Scholar
  99. 131.
    Djulbegovic B, Guyatt GH, Aschroft RE (2009) Epistemologic Inquiries in Evidence-Based Medicine. Cancer Control 16(2):158–168PubMedGoogle Scholar
  100. 132.
    Vlachos PK, Gelfand AE (1996) Issues in the Bayesian Design of clinical trials with multiple categorical endpoints. Proceedings of the ASA Section on Bayesian Statistical Science. http://citeseer.ist.psu.edu/60418.html. Cited 0 October 2007
  101. 134.
    Stangl D, Berry D (1998) Bayesian Statistics in Medicine: Where Are We and Where Should We Be Going? Invited Paper, Sankhya, Series B 60:176–195. http://citeseer.ist.psu.edu/401035.html. Cited 02 October 2007Google Scholar
  102. 135.
    Thall P, Simon RM, Estey EH (1996) New statistical strategy for monitoring safety and efficacy in single-arm clinical trials. J. Clin. Oncology 14:296–303Google Scholar
  103. 136.
    Evans CH, Ildstad ST (eds) (2001) Small clinical Trials: Issues and challenges. Institute of Medicine, National Academy Press, Washington DCGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  1. 1.Department of Biotechnics, Faculty of EngineeringSt. Istvan UniversityGodolloHungary
  2. 2.McKinsey & Co.BostonUSA
  3. 3.Oncotherm Inc.PatyHungary

Personalised recommendations